



## Comparative characterisation of two nitroreductases from *Giardia lamblia* as potential activators of nitro compounds

Müller, Joachim ; Rout, Samuel ; Leitsch, David ; Vaithilingam, Jathana ; Hehl, Adrian B ; Müller, Norbert

**Abstract:** *Giardia lamblia* is a protozoan parasite that causes giardiasis, a diarrhoeal disease affecting humans and various animal species. Nitro drugs such as the nitroimidazole metronidazole and the nitrothiazolide nitazoxanide are used for treatment of giardiasis. Nitroreductases such as GINR1 and GINR2 may play a role in activation or inactivation of these drugs. The aim of this work is to characterise these two enzymes using functional assays. For respective analyses recombinant analogues from GINR1 and GINR2 were produced in *Escherichia coli*. *E. coli* expressing GINR1 and GINR2 alone or together were grown in the presence of nitro compounds. Furthermore, pull-down assays were performed using HA-tagged GINR1 and GINR2 as baits. As expected, *E. coli* expressing GINR1 were more susceptible to metronidazole under aerobic and semi-aerobic and to nitazoxanide under semi-aerobic growth conditions whereas *E. coli* expressing GINR2 were susceptible to neither drug. Interestingly, expression of both nitroreductases gave the same results as expression of GINR2 alone. In functional assays, both nitroreductases had their strongest activities on the quinone menadione (vitamin K3) and FAD, but reduction of nitro compounds including the nitro drugs metronidazole and nitazoxanide was clearly detected. Full reduction of 7-nitrocoumarin to 7-aminocoumarin was preferentially achieved with GINR2. Pull-down assays revealed that GINR1 and GINR2 interacted in vivo forming a multienzyme complex. These findings suggest that both nitroreductases are multifunctional. Their main biological role may reside in the reduction of vitamin K analogues and FAD. Activation by GINR1 or inactivation by GINR2 of nitro drugs may be the consequence of a secondary enzymatic activity either yielding (GINR1) or eliminating (GINR2) toxic intermediates after reduction of these compounds.

DOI: <https://doi.org/10.1016/j.ijpddr.2015.03.001>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-110453>

Journal Article

Published Version




The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:

Müller, Joachim; Rout, Samuel; Leitsch, David; Vaithilingam, Jathana; Hehl, Adrian B; Müller, Norbert (2015). Comparative characterisation of two nitroreductases from *Giardia lamblia* as potential activators

of nitro compounds. *International Journal for Parasitology: Drugs and Drug Resistance*, 5(2):37-43.  
DOI: <https://doi.org/10.1016/j.ijpddr.2015.03.001>



## Comparative characterisation of two nitroreductases from *Giardia lamblia* as potential activators of nitro compounds



Joachim Müller<sup>a</sup>, Samuel Rout<sup>b</sup>, David Leitsch<sup>a</sup>, Jathana Vaithilingam<sup>a</sup>, Adrian Hehl<sup>b</sup>, Norbert Müller<sup>a,\*</sup>

<sup>a</sup> Institute of Parasitology, Vetsuisse Faculty, University of Berne, Länggass-Strasse 122, CH-3012 Berne, Switzerland

<sup>b</sup> Institute of Parasitology, Eukaryotic Microbiology, University of Zürich, Winterthurerstrasse 266a, CH-8057 Zürich, Switzerland

### ARTICLE INFO

#### Article history:

Received 5 February 2015

Received in revised form 12 March 2015

Accepted 16 March 2015

Available online 25 March 2015

#### Keywords:

Mode of action of nitro compounds

Functional assays

Nitroreduction

### ABSTRACT

*Giardia lamblia* is a protozoan parasite that causes giardiasis, a diarrhoeal disease affecting humans and various animal species. Nitro drugs such as the nitroimidazole metronidazole and the nitrothiazolide nitazoxanide are used for treatment of giardiasis. Nitroreductases such as GINR1 and GINR2 may play a role in activation or inactivation of these drugs. The aim of this work is to characterise these two enzymes using functional assays. For respective analyses recombinant analogues from GINR1 and GINR2 were produced in *Escherichia coli*. *E. coli* expressing GINR1 and GINR2 alone or together were grown in the presence of nitro compounds. Furthermore, pull-down assays were performed using HA-tagged GINR1 and GINR2 as baits. As expected, *E. coli* expressing GINR1 were more susceptible to metronidazole under aerobic and semi-aerobic and to nitazoxanide under semi-aerobic growth conditions whereas *E. coli* expressing GINR2 were susceptible to neither drug. Interestingly, expression of both nitroreductases gave the same results as expression of GINR2 alone. In functional assays, both nitroreductases had their strongest activities on the quinone menadione (vitamin K<sub>3</sub>) and FAD, but reduction of nitro compounds including the nitro drugs metronidazole and nitazoxanide was clearly detected. Full reduction of 7-nitrocoumarin to 7-aminocoumarin was preferentially achieved with GINR2. Pull-down assays revealed that GINR1 and GINR2 interacted in vivo forming a multienzyme complex. These findings suggest that both nitroreductases are multifunctional. Their main biological role may reside in the reduction of vitamin K analogues and FAD. Activation by GINR1 or inactivation by GINR2 of nitro drugs may be the consequence of a secondary enzymatic activity either yielding (GINR1) or eliminating (GINR2) toxic intermediates after reduction of these compounds.

© 2015 Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

### 1. Introduction

*Giardia lamblia* (syn. *Giardia duodenalis*; *Giardia intestinalis*), a flagellated protozoan, is the most common causative agent of persistent diarrhoea worldwide (Thompson, 2000; Robertson et al., 2010). Currently, anti-giardial chemotherapy is performed using a couple of effective drugs, namely, the nitroheterocyclic drugs tinidazole, metronidazole, furazolidone, quinacrine, the aminoglycoside paromomycin, and the benzimidazole albendazole (Wright et al., 2003; Lalle, 2010). Furthermore, the nitrothiazolide nitazoxanide has been introduced as an alternative option (Hemphill et al., 2006).

As frequently hypothesised, metronidazole and other nitro drugs are reduced to a nitro-radical. According to one of these hypotheses, electrons are provided by the enzyme pyruvate:flavodoxin/ferredoxin

oxidoreductase (PFOR), representing a protein that is lacking in higher eukaryotic cells (Brown et al., 1998; Horner et al., 1999). Referring to this model, the electrons are transferred via PFOR from pyruvate to ferredoxin. The resulting reduced ferredoxin is then re-oxidised by ferredoxin:NAD-oxidoreductase transferring its electrons to NAD(P). The resulting NAD(P)H serves as a redox partner for subsequent reactions such as the reduction of O<sub>2</sub> by NAD(P)H oxidase (Brown et al., 1998). Nitro drugs may interfere in this pathway and capture electrons directly from the reduced ferredoxin or from the NAD(P)H-oxidase. This process leads to the accumulation of toxic radicals that cause irreversible damage in the parasite. Further evidence for PFOR being a major target for nitro drugs in *Giardia* comes from metronidazole-resistant isolates with lower PFOR expression levels (Upcroft and Upcroft, 2001).

Since a few years, however, evidence is emerging that PFOR may not represent the exclusive target of nitro drugs in semi-aerobic or anaerobic pathogens. In the case of *T. vaginalis*, metronidazole and other nitroimidazoles were shown to covalently bind, and thus inactivate, proteins involved in the thioredoxin reductase pathway. Resistant cells compensate this blocking by re-regulating PFORs and

\* Corresponding author. Institute of Parasitology, Vetsuisse Faculty Berne, University of Berne, Länggass-Strasse 122, CH-3012 Berne, Switzerland. Tel.: +41 31 6312474; fax: +41 31 6312477.

E-mail address: [norbert.mueller@vetsuisse.unibe.ch](mailto:norbert.mueller@vetsuisse.unibe.ch) (N. Müller).

other enzymes participating in oxidoreductive processes. Accordingly, down-regulation of PFOR seems not to be a prerequisite but rather a consequence of resistance formation (Leitsch et al., 2009). Moreover, our investigations on *Giardia* cell lines resistant to nitro drugs have demonstrated that resistance is not necessarily linked to down-regulation of PFOR (Müller et al., 2007a, 2008). Although some nitro drugs are supposed to interact with PFOR in a direct manner, direct reduction of the nitro group via ferredoxin is rather unlikely. Accordingly, catalysis of this reaction by nitroreductases is a more realistic scenario (Roldán et al., 2008).

Nitroreductases belong to the enzymatic repertoire of many archaeobacteria and eubacteria (Nixon et al., 2002), where they contribute to the assimilation of nitro compounds as carbon sources (Johnson and Spain, 2003; Luque-Almagro et al., 2006). From a mechanistic point of view, nitroreductases are divided into two classes, namely oxygen-sensitive and oxygen-insensitive nitroreductases (Roldán et al., 2008). Oxygen-sensitive nitroreductases transfer electrons one by one from NAD(P)H to the nitro group. In presence of oxygen, the intermediate radicals are re-oxygenated. Thus, there is NAD(P)H consumption without nitroreduction, and the reaction looks most like the one catalysed by a NAD(P)H oxydase. Oxygen-insensitive nitroreductases catalyse the full reduction of nitro compounds into the corresponding amines by two-electron transfers. Also this type of reaction produces toxic intermediates, namely, nitroso or hydroxylamine intermediates (Moreno and Docampo, 1985).

In anaerobic or microaerophilic pathogens, nitroreductases are also well documented as resistance factors. In *Helicobacter pylori*, resistance to metronidazole is associated with loss-of-function mutations of the gene *rdxA* encoding an oxygen-insensitive nitroreductase (Goodwin et al., 1998), which reduces metronidazole under anaerobic conditions (Olekhovich et al., 2009). Other nitroreductases are found in enteric bacteria including *Escherichia coli* (Lee et al., 1994; Zenno et al., 1996a, 1996b, 1996c; Guillén et al., 2009; Tavares et al., 2009; Yanto et al., 2010).

Nitroreductases have also been identified in microaerophilic or anaerobic eukaryotic parasites such as *Entamoeba histolytica* and *G. lamblia*. These organisms may have acquired the respective genes from prokaryotes by lateral transfer (Nixon et al., 2002). *G. lamblia* (clone WB C6) harbours two genes encoding nitroreductases GINR1 (accession N° EDO80257; G150803-22677, referred to as Fd-NR2 in the *Giardia* database) and GINR2 (accession N° XM\_764091.1; G150803-6175, referred to as Fd-NR1 in the *Giardia* database). The polypeptide sequence of GINR2 is rather similar to that one of GINR1. Both proteins contain a ferredoxin domain with four Fe-S-clusters at their N-terminus and a nitro-FMN-reductase domain at their C-terminus. Our previous results suggest that both enzymes have a different action on nitro drugs: GINR1 behaving as an activator (Müller et al., 2007b; Nillius et al., 2011), GINR2 more as an inactivator (Müller et al., 2013). The biological role of these enzymes is, however, completely unclear.

Here, we present results from functional assays showing that both nitroreductases are multifunctional with strong quinone reductase activities. Moreover, we show that both nitroreductases interact in vivo forming a multienzyme complex.

## 2. Materials and methods

### 2.1. Tissue culture media, biochemicals and drugs

If not otherwise stated, all biochemical reagents were from Sigma (St Louis, MO, USA). 7-Nitrocoumarin was purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). Nitazoxanide was synthesised at the Department of Chemistry and Biochemistry, University of Berne (kindly provided by Ch. Leumann). The nitroimidazole C17 was kindly provided by J. A. Upcroft (Molecular

Genetics Laboratory, Queensland Institute of Medical Research, Brisbane, Australia). CB1954 was purchased from Santa Cruz Biotechnology. The compounds were kept as 100 mM stock solutions in DMSO at  $-20^{\circ}\text{C}$ .

### 2.2. Overexpression of recombinant GINR1 and 2 in *E. coli* and His-Tag-purification

Overexpression of recombinant GINR1 and GINR2 in *E. coli* BL21 (DE3) and their purification by His-Tag-affinity-chromatography was performed as previously described (Müller et al., 2007b, 2013).

### 2.3. Overexpression of recombinant HA-tagged GINR1 and 2 in *G. lamblia*

Cloning of PCR-amplified GINR1 and GINR2 open reading frames into the XbaI and PacI sites from vector pPacV-Integ (Jiménez-García et al., 2008) was essentially done as previously described (Müller et al., 2007b, 2009). Briefly, GINR1 and GINR2-specific forward primer contained the XbaI site followed by the constitutive glutamate dehydrogenase (GDH) promoter sequence (Davis-Hayman and Nash, 2002) (Table S1). In the reverse primer, a sequence encoding three consecutive human influenza haemagglutinin (HA) tags was introduced 5' of the PacI site (Table S1). PCRs for amplification of GINR1 and GINR2 open reading frames, insertion of amplification products into XbaI and PacI sites from pPacV thus yielding pPacV-GINR1-3xHA or pPacV-GINR2-3xHA, and transfection of *G. lamblia* WBC6 with SwaI-linearised recombinant plasmids were performed as previously described (Müller et al., 2007b, 2009).

### 2.4. Co-immunoprecipitation assay with HA-tagged nitroreductases

*G. lamblia* WBC6 GINR1-3xHA and GINR2-3xHA transgenic trophozoites were grown under anaerobic condition in triple flasks (Nunc, cat. 132867). The parasites were harvested by chilling in ice water for an hour followed by centrifugation ( $900 \times g$ , 10 min,  $4^{\circ}\text{C}$ ), washed in 50 ml ice cold PBS, and counted in a Neubauer chamber. For co-immunoprecipitation assays,  $10^9$  parasites were then re-suspended in a 15-ml-Falcon-tube containing 5 ml of lysis buffer (RIPA) consisting of 50 mM Tris pH 7.4, 150 mM NaCl, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS, 10 mM EDTA supplemented with 2 mM phenylmethylsulfonyl fluoride, PMSF and 1X Protease Inhibitor cocktail, PIC (cat. No. 539131, Calbiochem USA), and sonicated twice (60 pulses, 2 output control, 30% duty cycle and 60 pulses, 4 output control, 40% duty cycle). To solubilise the proteins, the Falcon tube was incubated on a rotating wheel (1 h,  $4^{\circ}\text{C}$ ). Cell lysate was transferred into 1.5 ml microtubes and the supernatant containing the solubilised protein was collected after high-speed centrifugation ( $14,000 \times g$ , 10 min,  $4^{\circ}\text{C}$ ). The solubilised protein fraction was diluted 1:1 with detergent-free RIPA lysis buffer supplemented with 2% Triton-X-100. To this diluted protein lysate, 40  $\mu\text{l}$  anti-HA agarose bead slurry from the Pierce HA Tag IP/Co-IP Kit (Thermo Fisher Scientific, Rockford, IL) were added and incubated at  $4^{\circ}\text{C}$  for 2 h on a rotating wheel in order to allow the HA-tagged proteins to bind to the agarose beads. Samples were pulse-centrifuged at  $3500 \times g$  at  $4^{\circ}\text{C}$  and 100  $\mu\text{l}$  was stored as flow through control. Samples were washed 4 times with 3 ml of Tris-Buffered Saline (TBS) supplemented with 0.1% Triton-X-100 and once with 3 ml PBS. The agarose slurry was re-suspended in 350  $\mu\text{l}$  PBS and transferred into the spin column provided in the kit and pulse-fused at  $14,000 \times g$  for 10 s at  $4^{\circ}\text{C}$ . The agarose beads (boiled beads) were then re-suspended in 30  $\mu\text{l}$  PBS and transferred into a 1.5 ml microtubes and stored at  $-20^{\circ}\text{C}$  overnight for further analysis.

### 2.5. Protein analysis and sample preparation for mass spectrometry

For SDS-PAGE according to (Laemmli (1970), the samples collected as described above were suspended in one volume of SDS-PAGE sample buffer containing 100 mM dithiothreitol, and boiled for 5 min followed by high speed centrifugation ( $14,000 \times g$ , 10 min, RT). For MS analysis, 25  $\mu$ l of boiled bead sample were loaded on a 12% polyacrylamide gel under reducing conditions. The gel (see Fig. S1) was then stained with Instant blue (Expedeon, San Diego, CA), de-stained with sterile water, and subsequently sent to the Functional Genomics Center Zürich for mass spectrometry. For immunoblot analysis, approximately  $10^7$  trophozoites were processed and samples were collected as described above. Immunoblots were performed with rabbit anti-GINR1 (Nillius et al., 2011) and mouse-anti-HA (Roche Diagnostics, Rotkreuz, Switzerland) antibodies as described before (Nillius et al., 2011).

### 2.6. Mass spectrometry

Gel lanes (see Fig. S1) were cut in 8 equal sections. Each section was further diced into smaller pieces and washed twice with 100  $\mu$ l of 100 mM ammonium bicarbonate/50% acetonitrile for 15 min at 50 °C. The sections were dehydrated with 50  $\mu$ l of acetonitrile. The supernatants of the washing and de-hydration steps were discarded. The gel pieces were re-hydrated with 20  $\mu$ l trypsin solution (5 ng/ $\mu$ l in 10 mM Tris/2 mM  $\text{CaCl}_2$  at pH 8.2) and 40  $\mu$ l buffer (10 mM Tris/2 mM  $\text{CaCl}_2$  at pH 8.2). Microwave-assisted digestion was performed for 30 min at 60 °C with the microwave power set to 5 W (CEM Discover, CEM Corp., USA). Supernatants were collected in fresh tubes and the gel pieces were extracted with 150  $\mu$ l of 0.1% trifluoroacetic acid/50% acetonitrile. Supernatants were combined, dried, and the samples were dissolved in 20  $\mu$ l of 0.1% formic acid before being transferred to the autosampler vials for liquid chromatography-tandem mass spectrometry, 7 to 9  $\mu$ l were injected. Samples were measured on a Q-exactive mass spectrometer (Thermo Fisher Scientific) equipped with a nanoAcquity UPLC (Waters Corporation, Milford, MA). Peptides were trapped on a trap column (Symmetry C18, 5  $\mu$ m, 180  $\mu$ m  $\times$  20 mm, Waters Corporation) before they were separated on a BEH300 C18, 1.7  $\mu$ m, 75  $\mu$ m  $\times$  150 mm column (Waters Corporation) by applying a gradient formed between solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). On the mass spectrometer, a gradient starting at 1% solvent B and increasing to 40% within 60 min was established. Database searches were performed using the MASCOT search program against the *Giardia* database (<http://giardiadb.org/giardiadb/>) with a concatenated decoy database supplemented with commonly observed contaminants and the Swissprot database to increase size of the database. The identified hits were then loaded onto the Scaffold Viewer version 4 (Proteome Software, Portland, USA) and the hits were filtered based on high stringency parameters, namely, minimal mascot score of 95 for peptide probability, a protein probability of 95% and a minimum of 2 unique peptides per protein.

### 2.7. Quantification of nitroreductase activity

For enzymatic quantification, the nitroreductase activity was measured in 96-well microtiter plates containing 100  $\mu$ l of a reaction mix containing buffer (50 mM Tris-Cl<sup>-</sup>, pH 7.0), 0.1 mM of the compounds to be tested, 0.5 mM thiazolyl blue tetrazolium (MTT), 0.5 mM NADH or NADPH and 0.1 to 0.2  $\mu$ g of the recombinant enzymes. The plates were incubated at 37 °C under aerobic conditions or in an anaerobic growth chamber. Substrate and enzyme blanks were included. After different time points, the reaction was stopped by adding 100  $\mu$ l of pure ethanol thus solubilising the product formed by the reduction of MTT, formazan. The absorbance at 590 nm was read on a 96-well plate spectrophotometer

(Versamax; Molecular Devices, Sunnyvale, CA). After subtraction of substrate and enzyme blanks, nitroreductase activity was expressed as  $\Delta A_{590}/\text{min}/\text{mg}$  (Prochaska and Santamaria, 1988).

The reduction of 7-nitrocoumarin to 7-aminocoumarin was quantified using the reaction mix as described above, but without MTT, with the same volumes and under the same conditions of incubation. Enzyme and substrate blanks were included. The reaction was stopped by adding 100  $\mu$ l of 50 mM HCl. The resulting solution had pH 2 resulting in full protonation of 7-aminocoumarin which was quantified by fluorimetry with excitation at 365 nm and emission at 455 nm (Wagner, 2009) using a 96-well-multimode plate reader (Enspire; Perkin-Elmer, Waltham, MA).

### 2.8. Determination of drug susceptibility in *E. coli*

Drug susceptibility of recombinant *E. coli* BL21 (DE3) lines (Invitrogen, Carlsbad, CA, USA) expressing either GINR1 (recombinant plasmid pGINR1), GINR2 (pGINR2), glucuronidase A (pGusA) alone (Nillius et al., 2011; Müller et al., 2013) or both nitroreductases (this study, see below) were tested as described (Müller et al., 2013). Single gene expression was achieved in vector system pET151 Directional TOPO® (Invitrogen) containing the ampicillin resistance marker for selection of transformants and allowing IPTG-inducible over-expression of recombinant proteins (see pET151 Directional TOPO® manual provided by the manufacturer) as described (Müller et al., 2013). In order to achieve double transfectants expressing both nitroreductases, the following cloning strategies were chosen: (i) the entire pET151 Directional TOPO® expression cassettes carrying GINR1 and GusA open reading frames were amplified by PCR using T7 forward (5'-TAATACGACTCACTATAGGG-3') and T7 reverse (5'-TAGTTATTGCTCAGCGGTGG-3') primers (annealing to regions flanking the expression cassette of pET151 Directional TOPO®) and pGINR1 and pGusA as DNA templates. (ii) PCR products were used for re-cloning of GINR1 and GusA into pCR-Blunt II-TOPO® (Invitrogen) containing a kanamycin resistance marker. (iii) This re-cloning step provided plasmid constructs, pGINR1-Kan<sup>R</sup> and pGusA-Kan<sup>R</sup>, suitable for subsequent transformation of ampicillin-resistant BL21 (DE3)/pGINR2, and BL21 (DE3)/pGusA strains by selection for ampicillin (100  $\mu$ g/ml)/kanamycin (50  $\mu$ g/ml) double-resistant clones. *E. coli* BL21 (DE3) carrying pGINR1, pGINR2, pGusA, pNR1-Kan<sup>R</sup>/pGINR2 and pGusA-Kan<sup>R</sup>/pGusA were tested under aerobic or microaerobic (5% O<sub>2</sub>, 10% CO<sub>2</sub>, 85% N<sub>2</sub>) conditions by a conventional disc diffusion agar procedure as described (Müller et al., 2013). Growth inhibition zone diameters were determined and the inhibition zone around the disc was calculated (in mm<sup>2</sup>).

### 2.9. Statistical methods


Statistical analysis of the results was done based on the tools from the open source software package R (R Core Team, 2012). Differences exhibiting *p* values < 0.01 were considered significant.

## 3. Results

### 3.1. *E. coli* expressing recombinant GINR1 and GINR2 have different susceptibilities to nitro drugs

We generated recombinant *E. coli* lines producing GINR1 or GINR2 alone (Müller et al., 2013) or both (this study). As a control, we have created recombinant lines expressing glucuronidase A (Gus) alone (Müller et al., 2013) or double (Gus/Gus) (this study). In a pilot experiment, overproduction of proteins induced by IPTG strongly reduced growth of *E. coli*. Accordingly, non-induced, recombinant *E. coli* cultures were chosen for growth inhibition assays as described earlier (Nillius et al., 2011). With these five strains, disc diffusion assays were performed with metronidazole, nitazoxanide






**Fig. 1.** Susceptibility of *E. coli* BL21 (DE3) expressing GusA as a control (Gus), GINR1 (NR1), and GINR2 (NR2), two GusA (Gus/Gus), or both nitroreductases (NR1/NR2) to metronidazole (MET) and to nitazoxanide (NTZ). Tetracycline (TET) was included as a positive control. Plates with different cell lines exposed to discs containing the drugs were incubated under aerobic (A) or semi-aerobic (B) conditions. After 24 h, diameters of inhibition zones were determined. Mean values  $\pm$  SE are given for 3 replicates. Values marked by asterisks are significantly different from the controls, i.e. to Gus for the single transformants and to Gus/Gus for the double transformant (paired *t*-test, two-sided, \**p* < 0.01).

or tetracyclin as a positive control under aerobic or semi-aerobic conditions. Under aerobic as well as semi-aerobic growth conditions, metronidazole clearly inhibited growth of control strains transformed with Gus or Gus/Gus. In the presence of GINR1 alone, this susceptibility was significantly enhanced. Bacteria transformed with GINR2 alone or with both nitroreductases were completely resistant to metronidazole. Under aerobic conditions, nitazoxanide did not affect growth of bacteria. Under semi-aerobic conditions, however, bacteria expressing GINR1 exhibited a significantly higher susceptibility to nitazoxanide than control bacteria. Other inserts than GINR1 had no effects. There were no significant effects in nitroreductase-transformed strains vs. control strains in the presence of tetracycline (Fig. 1).

### 3.2. Recombinant GINR1 and GINR2 are quinone reductases

The results obtained with metronidazole clearly suggested a role of both nitroreductases under aerobic conditions. Was their role



**Fig. 2.** Activity of recombinant *G. lamblia* nitroreductases GINR1 (NR1) and GINR2 (NR2) with menadione (Men) or dinitrotoluene (DNT) as substrates (0.1 mM). DMSO was included as a solvent control, thus as a substrate blank. Functional assays were performed with NADH as an electron donor and MTT as chromogenic electron acceptor. The reaction was performed at 37 °C under normal atmosphere (aerobic) or in an anaerobic chamber (100% N<sub>2</sub>; anaerobic) and stopped after 2 h addition of one volume pure ethanol. Mean values ( $\pm$ SE) are given for three replicates.

thus restricted to the reduction of nitro compounds? To answer this question we implemented a functional assay based on the reduction of MTT to formazan by reduced nitrocompounds or quinones. In a first experiment, we incubated the assays in a 37 °C incubator under normal atmosphere or in an anaerobic culture chamber (100% N<sub>2</sub>). We offered NADH as electron donor, the quinone menadione and dinitrotoluene as electron acceptors or DMSO as a solvent control. Interestingly, both nitroreductases reduced menadione, and this even to much higher extents than dinitrotoluene. Both enzymes worked evenly well under anaerobic and under aerobic conditions (Fig. 2).

### 3.3. Both nitroreductases are NADH dependent and have a preference for menadione

We tested the preference for NADH or NADPH as electron donors with menadione or dinitrotoluene as a substrate. Both nitroreductases had clearly a preference for NADH with both substrates (Table 1). In a next step, we determined the activities of both enzymes on a series of compounds including FAD, dicoumarol, quinacrine and various nitro compounds including the antiangiogenic drugs metronidazole and nitazoxanide as well as C17 and CB1954. Furthermore, we included 7-nitrocoumarin, a compound yielding the highly fluorescent 7-aminocoumarin upon complete reduction.

The highest activities were observed for both enzymes with menadione as a substrate. Dicoumarol, a typical inhibitor of mammalian quinone reductases (Müller and Hemphill, 2011), had no effects. The second best substrate in our series was FAD. Ubiquinone (coenzyme Q10) was also reduced by both enzymes but with lower specific activities than menadione (Table 1).

With respect to nitro compounds as substrates, 7-nitrocoumarin was clearly the best. Interestingly, we could detect a reduction of all nitrocompounds with antiangiogenic activity, i.e. metronidazole, nitazoxanide, and C17. Dinitrophenol was only reduced by GINR1. GINR1 had a higher specific activity with all substrates (Table 1).

**Table 1**

Activity of recombinant *G. lamblia* nitroreductases (GINR1 and GINR2) with various nitro- and non-nitro compounds (0.1 mM) as substrates. Functional assays were performed with MTT as chromogenic electron acceptor. Electron donor was NADH or NADPH if specified. The reaction was performed at 37 °C and stopped after various time points by addition of one volume pure ethanol. Mean values ( $\pm$ SE) are given for three replicates after subtraction of enzyme and substrate blanks.


Substrate	GINR1 ( $\Delta A_{590} \text{ min}^{-1} \text{ mg prot}^{-1}$ )	GINR2
Menadione	22.9 $\pm$ 0.4	16.2 $\pm$ 0.2
Menadione NADPH	1.8 $\pm$ 0.2	0.2 $\pm$ 0.1
Dicoumarol	3.1 $\pm$ 0.2	0.8 $\pm$ 0.1
Menadione + dicoumarol	27.2 $\pm$ 0.3	14.5 $\pm$ 0.1
Ubiquinone (coenzyme Q <sub>10</sub> )	2.8 $\pm$ 0.1	1.8 $\pm$ 0.2
FAD	11.8 $\pm$ 0.4	8.9 $\pm$ 0.9
Dinitrotoluene	5.2 $\pm$ 0.3	2.8 $\pm$ 0.2
Dinitrotoluene NADPH	0.9 $\pm$ 0.3	0.3 $\pm$ 0.1
7-Nitrocoumarine	10.6 $\pm$ 0.3	6.5 $\pm$ 0.5
Dinitrophenol	5.9 $\pm$ 0.4	0.2 $\pm$ 0.1
Nitrophenol	2.9 $\pm$ 0.1	2.6 $\pm$ 0.1
Metronidazole	2.8 $\pm$ 0.2	1.7 $\pm$ 0.1
Nitazoxanide	2.7 $\pm$ 0.2	1.9 $\pm$ 0.1
CB1954	3.0 $\pm$ 0.1	1.7 $\pm$ 0.1
C17	2.1 $\pm$ 0.2	0.9 $\pm$ 0.1

### 3.4. 7-nitrocoumarin is fully reduced preferentially by GINR2

These results prompted us to investigate whether 7-aminocoumarin was fully reduced by both nitroreductases thus yielding the fluorescent 7-aminocoumarin. For this purpose, we performed the same assay as above without MTT, and quantified the fluorescent product. Although GINR2 had a lower specific activity in the assay as described above, it was twice as active as GINR1 in fully reducing 7-aminocoumarin. When added together, both enzymes were more active than the sum of the single activities (Fig. 3).

### 3.5. GINR1 and GINR2 interact in vivo

The synergistic effect of the two nitroreductases (see Fig. 3) suggested a physical interaction of the two enzymes prompting us to



**Fig. 3.** Activity of recombinant *G. lamblia* nitroreductases GINR1 (NR1) and GINR2 (NR2) with 7-nitrocoumarin as a substrate (0.1 mM) and with NADH as an electron donor. The reaction was performed at 37 °C with GINR1, GINR2 alone (125 ng each) or together (62.5 ng each) and stopped after various time points by addition of one volume HCl 0.05 M. Formation of 7-aminocoumarin was quantified by fluorimetry (excitation at 365 nm, emission at 455 nm). Mean values ( $\pm$ SE) are given for three replicates. Values marked by asterisks are significantly different from each other (paired *t*-test, two-sided, \**p* < 0.01).

**Table 2**

Proteins interacting with HA-tagged GINR1 in vivo. *G. lamblia* WBC6 was transformed with GINR1-3xHA. Crude extracts were affinity-purified using anti-HA-antibodies immobilised on beads followed by mass spectrometry. A control experiment was performed with crude extract from WBC6 expressing no recombinant protein. Only hits with highest stringency, namely, minimal mascot score of 95 for peptide probability, a protein probability of 95% and a minimum of 2 unique peptides per protein, are shown.

Name	Accession-N°	Molecular weight (kDa)	Unique peptides (N°)
Axoneme-associated protein GASP-180	GL50803_137716	175	4
Fructose-bisphosphate aldolase	GL50803_11043	35	3
GINR2 (Fd-NR1)	GL50803_6175	31	2
Hypothetical protein	GL50803_9183	214	2
TCP1-chaperon-subunit gamma	GL50803_17411	62	2
Phosphoglycerate kinase	GL50803_90872	44	2
Arginyl-tRNA-synthetase	GL50803_10521	70	2
Vacuolar ATP-synthase catalytic subunit A	GL50803_7532	72	2
Malate dehydrogenase	GL50803_3331	35	2

perform pull-down assays using HA-tagged GINR1 and GINR2 as baits. These pull-down assays were used for the identification of proteins which specifically bind to these nitroreductases in *G. lamblia*. Crude extracts from *G. lamblia* WBC6 expressing the corresponding constructs were affinity-purified using anti-HA-antibodies immobilised on beads followed by mass spectrometry. Under high stringency conditions, HA-tagged nitroreductase GINR1 co-purified with GINR2 and with a couple of other proteins including fructose-bisphosphate aldolase (Table 2). Conversely, HA-tagged GINR2 co-purified with GINR1 and with two other proteins, namely, fructose-bisphosphate aldolase and ornithine carbamoyl-transferase (Table 3). Immunoblot analysis using an antibody specific for GINR1 and an anti-HA antibody showed the presence of GINR1 in the immunoprecipitate of GINR2-3xHA. GINR2 was not cross reactive with GINR1. (Fig. 4).


## 4. Discussion

Like some other antiparasitic nitro drugs, metronidazole is considered as a prodrug that is activated by partial reduction. This reaction is supposed to form a toxic radical (Docampo and Moreno, 1984), or partially reduced nitroso- or hydroxylamine-intermediates (Moreno and Docampo, 1985), causing DNA damage (Sisson et al., 2000). Conversely, complete reduction results in detoxification of nitro compounds thus allowing various bacteria to use toxic compounds such as trinitrotoluene as carbon sources (Kutty and Bennett, 2005). Our results obtained with MTT as a final electron acceptor suggest that both nitroreductases are multifunctional and able to

**Table 3**

Proteins interacting with HA-tagged GINR2 in vivo. *G. lamblia* WBC6 was transformed with GINR2-3xHA. Crude extracts were affinity-purified using anti-HA-antibodies immobilised on beads followed by mass spectrometry. A control experiment was performed with crude extract from WBC6 expressing no recombinant protein. Only hits with highest stringency, namely, minimal mascot score of 95 for peptide probability, a protein probability of 95% and a minimum of 2 unique peptides per protein, are shown.

Name	Accession-N°	Molecular weight (kDa)	unique peptides (N°)
GINR1 (Fd-NR2)	GL50803_22677	29	15
Fructose-bisphosphate aldolase	GL50803_11043	35	2
Ornithine carbamoyl-transferase	GL50803_10311	36	2



**Fig. 4.** Immunoblot with anti-GINR1 and anti HA-antibodies of immunoprecipitates from untransformed WBC6 (control), WBC6 transformed with GINR1-3xHA as a bait, and WBC6 transformed with GINR2-3xHA as a bait. Trophozoites were processed as described. The position of molecular weight markers is indicated in kDa.

use a variety of nitro compounds as substrates. With 7-nitrocoumarin as a substrate, full reduction to the corresponding 7-aminocoumarin can be investigated (Wagner, 2009). In our hands, GINR2 is twice as effective as GINR1 in this reaction indicating that it performs the full reduction rather than a partial reduction. When mixed, both enzymes act synergistically.

In *E. coli*, expression of GINR1 increases the susceptibility to nitazoxanide exclusively under semi-aerobic growth conditions whereas susceptibility to metronidazole is increased under semi-aerobic and aerobic conditions. In contrast, GINR2 decreases the susceptibility to metronidazole under both growth conditions confirming previous results (Nillius et al., 2011; Müller et al., 2013). Interestingly, expression of both enzymes has the same effects as expression of GINR2 alone suggesting that *E. coli* BL21(DE3) is able to express endogenous nitroreductases even under aerobic growth conditions what is fully in frame with previously published results (Zenno et al., 1996a, 1996c; Valle et al., 2012). While these endogenous nitroreductases reduce metronidazole to toxic intermediates, GINR2 acts antagonistically and eliminates metronidazole toxicity in *E. coli*. Susceptibility of *E. coli* to metronidazole has been reported earlier (Olekhnovich et al., 2009; Nillius et al., 2011). The results with nitroreductase-expressing *E. coli* and the results obtained with 7-nitrocoumarin in functional assays suggest that GINR1 preferentially performs a partial reduction of nitro compounds yielding toxic intermediates. Conversely, GINR2 is able to entirely reduce a nitro compound thus generating a non-toxic end product, e.g. the corresponding amine.

Our experiments show, however, that nitro compounds are not the best substrates for both enzymes having highest activities on menadione as substrate. This quinone reductase activity is not inhibited by dicoumarol as it is the case for typical mammalian nitroreductases such as the human quinone reductase NQO1 (Müller and Hemphill, 2011). Moreover, both enzymes reduce free FAD. Similar multifunctional nitroreductases have been identified in various bacteria including *E. coli* (Zenno et al., 1996a, 1996b, 1996c), *Lactobacillus plantarum* (Guillén et al., 2009), *Salmonella typhimurium* (Yanto et al., 2010) and in eukaryotes such as *Trypanosoma cruzi* (Hall et al., 2012). The genome of *G. lamblia* WBC6 contains three putative NADPH dependent quinone reductases, namely, GI50803\_15004 (18.6 kDa), GI50803\_17150 (18.5 kDa), and GI50803\_17151 (19.5 kDa). Only one, GI50803\_15004, has been previously characterised in detail. This

enzyme reduces menadione using NADPH as preferred electron donor (Sanchez et al., 2001).

The biological function of GINR1 and GINR2 could be the reduction of quinones and other heterocyclic compounds in essential steps of intermediate metabolism. Menadione is not a quinone present in *Giardia* and is even toxic (Paget et al., 2004). This toxicity may be due to a partial reduction of menadione to the corresponding semiquinone. Other potential substrates such as FAD and ubiquinone (Ellis et al., 1994) are, however, present in *Giardia* and play an important role in intermediate metabolism.

This could explain why knock-down approaches have failed, so far in our hands, and why a nitroreductase is essential for *Leishmania donovani* (Voak et al., 2013). From an evolutionary point of view, the reduction of nitro compounds could be a side effect without negative selective pressure until a nitro compound yielding toxic intermediates after reduction comes into play. Then, the presence of an otherwise beneficial activity turns into a disaster for the cell. In the presence of sublethal concentrations of the nitro compound, resistance formation is then achieved not by a mere down-regulation of the nitroreductase responsible for the toxic intermediate formation, but rather by a complete re-organisation of cellular metabolism as exemplified by the resistance formation of WBC6 against nitazoxanide (Müller et al., 2008).

Pull-down assays with both nitroreductases as baits and immunoblot analysis show that both enzymes interact with each other. Moreover, they may also interact with fructose-bisphosphate aldolase, a key enzyme of glycolysis. The significance of this finding is unclear and will be studied in further immunoprecipitation experiments using fructose-bis-phosphate aldolase as a bait.

Novel promising techniques like conditional knock-outs (Wampfler et al., 2014) could open the way to understand the biological function of nitroreductases in *G. lamblia*.

## Acknowledgements

We would like to thank The Functional Genomics Center Zürich (FGCZ) for highly valuable technical support. We also wish to thank A. Hemphill (Institute of Parasitology, University of Berne, Berne, Switzerland) for proofreading of the manuscript and C. Huber as well as V. Balmer (Institute of Parasitology, University of Berne, Berne, Switzerland) for technical assistance. This study was supported by grants from the Swiss National Science Foundation (grants No. 31003A\_138353 [NM, JM] and No. 31-140803/1 [AH]) and the Austrian Science Fund (project J3492 1 [DL]).

## Conflict of interest

The authors declared that there is no conflict of interest.

## AppendixSupplementary material

Supplementary data to this article can be found online at doi:10.1016/j.ijpddr.2015.03.001.

## References

- Brown, D.M., Upcroft, J.A., Edwards, M.R., Upcroft, P., 1998. Anaerobic bacterial metabolism in the ancient eukaryote *Giardia duodenalis*. *Int. J. Parasitol.* 28, 149–164.
- Davis-Hayman, S.R., Nash, T.E., 2002. Genetic manipulation of *Giardia lamblia*. *Mol. Biochem. Parasitol.* 122, 1–7.
- Docampo, R., Moreno, S.N., 1984. Free radical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on *Trypanosoma cruzi*. *Rev. Infect. Dis.* 6, 223–238.
- Ellis, J.E., Setchell, K.D., Kaneshiro, E.S., 1994. Detection of ubiquinone in parasitic and free-living protozoa, including species devoid of mitochondria. *Mol. Biochem. Parasitol.* 65, 213–224.



- Goodwin, A., Kersulyte, D., Sisson, G., Veldhuyzen van Zanten, S.J., Berg, D.E., Hoffman, P.S., 1998. Metronidazole resistance in *Helicobacter pylori* is due to null mutations in a gene (*rdxA*) that encodes an oxygen-insensitive NADPH nitroreductase. *Mol. Microbiol.* 28, 383–393.
- Guillén, H., Curiel, J.A., Landete, J.M., Muñoz, R., Herraiz, T., 2009. Characterization of a nitroreductase with selective nitroreduction properties in the food and intestinal lactic acid bacterium *Lactobacillus plantarum* WCFS1. *J. Agric. Food Chem.* 57, 10457–10465.
- Hall, B.S., Meredith, E.L., Wilkinson, S.R., 2012. Targeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs. *Antimicrob. Agents Chemother.* 56, 5821–5830.
- Hemphill, A., Müller, J., Esposito, M., 2006. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. *Expert Opin. Pharmacother.* 7, 953–964.
- Horner, D.S., Hirt, R.P., Embley, T.M., 1999. A single eubacterial origin of eukaryotic pyruvate: ferredoxin oxidoreductase genes: implications for the evolution of anaerobic eukaryotes. *Mol. Biol. Evol.* 16, 1280–1291.
- Jiménez-García, L.F., Zavala, G., Chávez-Munguía, B., Ramos-Godínez Mdel, P., López-Velázquez, G., Segura-Valdez Mde, L., et al., 2008. Identification of nucleoli in the early branching protist *Giardia duodenalis*. *Int. J. Parasitol.* 1297–1304.
- Johnson, G.R., Spain, J.C., 2003. Evolution of catabolic pathways for synthetic compounds: bacterial pathways for degradation of 2,4-dinitrotoluene and nitrobenzene. *Appl. Microbiol. Biotechnol.* 62, 110–123.
- Kutty, R., Bennett, G.N., 2005. Biochemical characterization of trinitrotoluene transforming oxygen-insensitive nitroreductases from *Clostridium acetobutylicum* ATCC 824. *Arch. Microbiol.* 184, 158–167.
- Laemmli, U.K., 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227, 680–685.
- Lalle, M., 2010. Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives. *Infect. Disord. Drug Targets* 10, 283–294.
- Lee, H., Cherg, S.H., Liu, T.Y., 1994. Bacterial mutagenicity, metabolism, and DNA adduct formation by binary mixtures of benzo[a]pyrene and 1-nitropyrene. *Environ. Mol. Mutagen.* 24, 229–234.
- Leitsch, D., Kolarich, D., Binder, M., Stadlmann, J., Altmann, F., Duchêne, M., 2009. Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. *Mol. Microbiol.* 72, 518–536.
- Luque-Almagro, V.M., Blasco, R., Paloma Sáez, L., Roldán, M.D., Moreno-Vivián, C., Castello, F., et al., 2006. Interactions between nitrate assimilation and 2,4-dinitrophenol cometabolism in *Rhodobacter capsulatus* E1F1. *Curr. Microbiol.* 53, 37–42.
- Moreno, S.N., Docampo, R., 1985. Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis. *Environ. Health Perspect.* 64, 199–208.
- Müller, J., Hemphill, A., 2011. Identification of a host cell target for the thiazolide class of broad-spectrum anti-parasitic drugs. *Exp. Parasitol.* 128, 145–150.
- Müller, J., Sterk, M., Hemphill, A., Müller, N., 2007a. Characterization of *Giardia lamblia* WB C6 clones resistant to nitazoxanide and to metronidazole. *J. Antimicrob. Chemother.* 60, 280–287.
- Müller, J., Wastling, J., Sanderson, S., Müller, N., Hemphill, A., 2007b. A novel *Giardia lamblia* nitroreductase, GINR1, interacts with nitazoxanide and other thiazolides. *Antimicrob. Agents Chemother.* 51, 1979–1986.
- Müller, J., Ley, S., Felger, I., Hemphill, A., Müller, N., 2008. Identification of differentially expressed genes in a *Giardia lamblia* WB C6 clone resistant to nitazoxanide and metronidazole. *J. Antimicrob. Chemother.* 62, 72–82.
- Müller, J., Nillius, D., Hehl, A., Hemphill, A., Müller, N., 2009. Stable expression of *Escherichia coli*  $\beta$ -glucuronidase A (GusA) in *Giardia lamblia*: application to high-throughput drug susceptibility testing. *J. Antimicrob. Chemother.* 64, 1187–1191.
- Müller, J., Schildknecht, P., Müller, N., 2013. Metabolism of nitro drugs metronidazole and nitazoxanide in *Giardia lamblia*: characterization of a novel nitroreductase (GINR2). *J. Antimicrob. Chemother.* 68, 1781–1789.
- Nillius, D., Müller, J., Müller, N., 2011. Nitroreductase (GINR1) increases susceptibility of *Giardia lamblia* and *Escherichia coli* to nitro drugs. *J. Antimicrob. Chemother.* 66, 1029–1035.
- Nixon, J.E., Wang, A., Field, J., Morrison, H., McArthur, A.G., Sogin, M.L., et al., 2002. Evidence for lateral transfer of genes encoding ferredoxins, nitroreductases, NADH oxidase, and alcohol dehydrogenase 3 from anaerobic prokaryotes to *Giardia lamblia* and *Entamoeba histolytica*. *Eukaryot. Cell* 1, 181–190.
- Olekhovich, I.N., Goodwin, A., Hoffman, P.S., 2009. Characterization of the NAD(P)H oxidase and metronidazole reductase activities of the RdxA nitroreductase of *Helicobacter pylori*. *FEBS J.* 276, 3354–3364.
- Paget, T., Maroulis, S., Mitchell, A., Edwards, M.R., Jarroll, E.L., Lloyd, D., 2004. Menadione kills trophozoites and cysts of *Giardia intestinalis*. *Microbiology* 150, 1231–1236.
- Prochaska, H.J., Santamaria, A.B., 1988. Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. *Anal. Biochem.* 169, 328–336.
- R Core Team, 2012. R: A language and environment for statistical computing.
- Robertson, L.J., Hanevik, K., Escobedo, A.A., Mørch, K., Langeland, N., 2010. Giardiasis – why do the symptoms sometimes never stop? *Trends Parasitol.* 26, 75–82.
- Roldán, M.D., Pérez-Reinado, E., Castillo, F., Moreno-Vivián, C., 2008. Reduction of polynitroaromatic compounds: the bacterial nitroreductases. *FEMS Microbiol. Rev.* 32, 474–500.
- Sanchez, L.B., Elmendorf, H., Nash, T.E., Müller, M., 2001. NAD(P)H:menadione oxidoreductase of the amitochondriate eukaryote *Giardia lamblia*: a simpler homologue of the vertebrate enzyme. *Microbiology* 147, 561–570.
- Sisson, G., Jeong, J.Y., Goodwin, A., Bryden, L., Rossler, N., Lim-Morrison, S., et al., 2000. Metronidazole activation is mutagenic and causes DNA fragmentation in *Helicobacter pylori* and in *Escherichia coli* containing a cloned H. pylori RdxA(+) (Nitroreductase) gene. *J. Bacteriol.* 182, 5091–5096.
- Tavares, A.F., Nobre, L.S., Melo, A.M., Saraiva, L.M., 2009. A novel nitroreductase of *Staphylococcus aureus* with S-nitrosoglutathione reductase activity. *J. Bacteriol.* 191, 3403–3406.
- Thompson, R.C.A., 2000. Giardiasis as a re-emerging infectious disease and its zoonotic potential. *Int. J. Parasitol.* 30, 1259–1267.
- Upcroft, P., Upcroft, J.A., 2001. Drug targets and mechanisms of resistance in the anaerobic protozoa. *Clin. Microbiol. Rev.* 14, 150–164.
- Valle, A., Le Borgne, S., Bolívar, J., Cabrera, G., Cantero, D., 2012. Study of the role played by NfsA, NfsB nitroreductase and NemaA flavin reductase from *Escherichia coli* in the conversion of ethyl 2-(2'-nitrophenoxy)acetate to 4-hydroxy-(2H)-1,4-benzoxazin-3(4H)-one (D-DIBO), a benzohydroxamic acid with interesting biological properties. *Appl. Microbiol. Biotechnol.* 94, 163–171.
- Voak, A.A., Gobalakrishnapillai, V., Seifert, K., Balczó, E., Hu, L., Hall, B.S., et al., 2013. An essential type I nitroreductase from *Leishmania major* can be used to activate leishmanicidal prodrugs. *J. Biol. Chem.* 288, 28466–28476.
- Wagner, B.D., 2009. The use of coumarins as environmentally-sensitive fluorescent probes of heterogeneous inclusion systems. *Molecules* 14, 210–237.
- Wampfler, P.B., Faso, C., Hehl, A.B., 2014. The Cre/loxP system in *Giardia lamblia*: genetic manipulations in a binucleate tetraploid protozoan. *Int. J. Parasitol.* 44, 497–506.
- Wright, J.M., Dunn, L.A., Upcroft, P., Upcroft, J.A., 2003. Efficacy of anti-giardial drugs. *Expert Opin. Drug Saf.* 2, 529–541.
- Yanto, Y., Hall, M., Bommaris, A.S., 2010. Nitroreductase from *Salmonella typhimurium*: characterization and catalytic activity. *Org. Biomol. Chem.* 8, 1826–1832.
- Zenno, S., Koike, H., Kumar, A.N., Jayaraman, R., Tanokura, M., Saigo, K., 1996a. Biochemical characterization of NfsA, the *Escherichia coli* major nitroreductase exhibiting a high amino acid sequence homology to Frp, a *Vibrio harveyi* flavin oxidoreductase. *J. Bacteriol.* 178, 4508–4514.
- Zenno, S., Koike, H., Tanokura, M., Saigo, K., 1996b. Conversion of NfsB, a minor *Escherichia coli* nitroreductase, to a flavin reductase similar in biochemical properties to FRase I, the major flavin reductase in *Vibrio fischeri*, by a single amino acid substitution. *J. Bacteriol.* 178, 4731–4733.
- Zenno, S., Koike, H., Tanokura, M., Saigo, K., 1996c. Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from *Escherichia coli*, similar in biochemical properties to FRase I, the major flavin reductase in *Vibrio fischeri*. *J. Biochem.* 120, 736–744.